What to Expect From Edwards Lifesciences' Next Quarterly Earnings Report

Core Insights - Edwards Lifesciences Corporation (EW) is a leading company in structural heart disease and critical care monitoring, with a market cap of $48 billion and a diverse product portfolio including heart valves and monitoring devices [1] Financial Performance - Analysts expect EW to report a profit of $0.72 per share for the fiscal first quarter of 2026, reflecting a 12.5% increase from $0.64 per share in the same quarter last year [2] - For the full fiscal year 2026, EPS is projected to be $2.96, which is a 15.6% increase from $2.56 in fiscal 2025, with further growth expected to $3.30 in fiscal 2027, representing an 11.5% year-over-year increase [3] Earnings History - EW has shown a mixed earnings history, beating consensus estimates in three of the last four quarters, with reported earnings of $0.64, $0.67, $0.67, and $0.58 for the quarters ending March, June, September, and December 2025 respectively [4] - The company has had surprises ranging from +6.67% to -6.45% across these quarters, indicating variability in performance against expectations [4] Stock Performance - EW stock has outperformed the S&P 500 Index, gaining 15.5% over the past 52 weeks compared to the index's 13.4% increase, and has also outperformed the State Street Health Care Select Sector SPDR ETF [4] Growth Drivers - The company's growth is driven by strong momentum in Transcatheter Aortic Valve Replacement (TAVR) and the success of its SAPIEN valve iterations, with a target of $2 billion in sales from transcatheter mitral and tricuspid therapies (TMTT) by 2030 [5] Analyst Ratings - The consensus opinion on EW stock is moderately bullish, with 18 out of 30 analysts recommending a "Strong Buy" and an average price target of $96.44, suggesting a potential upside of 17.5% from current levels [6]